Cognitive impairment caused by chemotherapy. Malignant neoplasm of breast
Conditions
Interventions
Intervention 1: Intervention group:. Intervention 2: Control group:.
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Patients with stage II, I, or III breast cancer Receive at least one course of chemotherapy Age 18 to 70 years No cognitive problems at the beginning of the study
Exclusion criteria
Exclusion criteria: History of allergy to memantine Having cancer other than breast cancer Alcohol or drug use Advanced stages of breast cancer (stage IV – metastatic) If the patient is taking antidepressants, anti-anxiety medications, anti-seizure medications, or sedatives, the patient will be excluded from the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The frequency of people with cognitive impairment caused by chemotherapy. Timepoint: Assessment of cognitive impairment at the beginning of the study (before the intervention) and 3 and 6 months after chemotherapy. Method of measurement: Cognitive disorders related questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Reducing the rate of cognitive impairment caused by chemotherapy. Timepoint: After 3 and 6 months from the start of chemotherapy. Method of measurement: Cognitive disorders related questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNezhat Khanjani
Shiraz University of Medical Sciences
Outcome results
None listed